Movement Disorders

  • Eduardo C. Gonzalez
  • H. James Brownlee

Abstract

The movement disorders are a group of neurologic diseases characterized by varying degrees of degeneration in the basal ganglia, cerebellum, neostriatum, and higher brain stem. Likewise, these disorders manifest various effects on the neurotransmitter balance including dopamine, acetylcholine, and norepinephrine. It is thought that it is the neurotransmitter disturbances that account for variations in the clinical features of the movement disorders.

Keywords

Movement Disorder Progressive Supranuclear Palsy Essential Tremor Tardive Dyskinesia Cervical Dystonia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Martilla RJ. Epidemiology of Parkinson’s disease. In: Koller WC, editor. Handbook of Parkinson’s disease. New York: Marcel Dekker, 1989:35–50.Google Scholar
  2. 2.
    Cooper B. The epidemiology of primary degenerative dementia and related neurological disorders. Eur Arch Psychiatry Clin Neurosci 1991;240:223–33.PubMedCrossRefGoogle Scholar
  3. 3.
    Golbe LI. Young-onset Parkinson’s disease: a clinical review. Neurology 1991;41:168–73.PubMedCrossRefGoogle Scholar
  4. 4.
    Koller W, Zilkoski M. Parkinson’s disease. American Family Physician Monograph. Spring 1992.Google Scholar
  5. 5.
    Ward CD, Duvoisin RC, Ince SE, Nutt JD, Eldridge R, Calne DB. Parkinson’s disease in 65 pairs of twins and in a set of quadruplets. Neurology 1983;33:815–24.PubMedCrossRefGoogle Scholar
  6. 6.
    Parkinson J. Essay on the shaking palsy. London: Sherwood, Neely and Jones, 1817.Google Scholar
  7. 7.
    Stern M. The comprehensive management of Parkinson’s disease. New York: PMA Publishing, 1988:5.Google Scholar
  8. 8.
    Dooneief G, Mirabello E, Bell K, et al. An estimate of the incidence of depression in idiopathic Parkinson’s disease. Arch Neurol 1992;49:305–7.PubMedCrossRefGoogle Scholar
  9. 9.
    Gotham AM, Brown RG, Marsden CD: Depression in Parkinson’s disease: a quantitative and qualitative analysis. J Neurol Neurosurg Psychiatry 1986;49:381–9.PubMedCrossRefGoogle Scholar
  10. 10.
    Leverenz J, Sumi M. Parkinson’s disease in patients with Alzheimer’s disease. Arch Neurol 1986;43:662–4.PubMedCrossRefGoogle Scholar
  11. 11.
    Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427–42.PubMedCrossRefGoogle Scholar
  12. 12.
    Brooks DJ. Detection of preclinical Parkinson’s disease with PET. Neurology 1991;40 Suppl 3:24–8.Google Scholar
  13. 13.
    Tetrud JN, Langston JW. The effect of deprenyl (selegiline) on the natural history of Parkinson’s disease. Science 1989; 245:519–22.PubMedCrossRefGoogle Scholar
  14. 14.
    Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson’s disease. N Engl J Med 1989;321:1364–71.CrossRefGoogle Scholar
  15. 15.
    Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson’s disease. N Engl J Med 1993;328:176–83.CrossRefGoogle Scholar
  16. 16.
    Lee AJ. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson’s disease. BMJ 1995;311: 1602–7.CrossRefGoogle Scholar
  17. 17.
    Zornberg GL, Bodkin JA, Cohen BM. Severe adverse interaction between pethidine and selegiline. Lancet 1991;337:246.PubMedCrossRefGoogle Scholar
  18. 18.
    Consensus Conference. An algorithm for the management of Parkinson’s disease. Neurology 1994;44 Suppl 10:S9–52.Google Scholar
  19. 19.
    Kuvisevsky J, Tolosa E. Amantadine in Parkinson’s disease. In: Koller WC, Paulson G, editors. Therapy of Parkinson’s disease. New York: Marcel Dekker, 1990:143–60.Google Scholar
  20. 20.
    Rinne UK. Dopamine agonists as primary treatment in Parkinson’s disease. Adv Neurol 1987;45:519–23.PubMedGoogle Scholar
  21. 21.
    Goetz C. Dopaminergic agonists in the treatment of Parkinson’s disease. Neurology 1990;40 Suppl 3:50–4.Google Scholar
  22. 22.
    Ahlskog JE, Muenter MD. Pergolide: longterm use in Parkinson’s disease. Mayo Clin Proc 1988;63:679–87.Google Scholar
  23. 23.
    Caraceni T, Scigliano G, Musicco M. The occurrence of motor fluctuations in parkinsonian patients treated long term with levodopa: role of early treatment and disease progression. Neurology 1991;41:380–4.PubMedCrossRefGoogle Scholar
  24. 24.
    Diamond SG, Markham CH, Hoehn MM, McDowell FH, Muenter MD. Multi-center study of Parkinson mortality with early versus later dopa treatment. Ann Neurol 1987; 22:8–12.PubMedCrossRefGoogle Scholar
  25. 25.
    Ahlskog JE, Muenter MD, McManis PG, Bell GN, Bailey PA. Controlled-release sinemet (CR-4): a double-blind crossover study in patients with fluctuating Parkinson’s disease. Mayo Clin Proc 1988;63:876–86.PubMedCrossRefGoogle Scholar
  26. 26.
    Markham CH, Diamond SG. Modifications of Parkinson’s disease by long-term levodopa treatment. Arch Neurol 1986; 43:405–7.PubMedCrossRefGoogle Scholar
  27. 27.
    Pincus JH, Barry K. Influence of dietary protein on motor fluctuations in Parkinson’s disease. Arch Neurol 1987;44: 270–2.PubMedCrossRefGoogle Scholar
  28. 28.
    Koller WC, Hubble JP. Levodopa therapy in Parkinson’s disease. Neurology 1990;40 Suppl 3:40–7.Google Scholar
  29. 29.
    Nutt J. Levodopa-induced dyskinesia: review, observations and speculations. Neurology 1990;40:340–5.PubMedCrossRefGoogle Scholar
  30. 30.
    Obeso JA, Grandas F, Vaamonde J, et al. Motor complications associated with chronic levodopa therapy in Parkinson’s disease. Neurology 1989;39 Suppl 2:11–19.PubMedGoogle Scholar
  31. 31.
    Taylor AE, Saint-Cyr JA, Lang AE, Kenney FT. Parkinson’s disease and depression: a critical re-evaluation. Brain 1986; 109:279–92.PubMedCrossRefGoogle Scholar
  32. 32.
    Dogali M, Fazzini E, Kolodny E, et al. Neurology 1995;45: 753–61.PubMedCrossRefGoogle Scholar
  33. 33.
    Kelly PJ, Ahlskog JE, Goerss SJ, Daube JP, Duffy JR. Computer-assisted stereotactic ventralis lateralis thalomotomy with microelectrode recording control in patients with Parkinson’s disease. Mayo Clin Proc 1987;62:665–4.CrossRefGoogle Scholar
  34. 34.
    Madrazo I, Drucker-Colin R, Diaz V, Martinez-Mata J, Torres C, Becerril JJ. Open microsurgical autograft of adrenal medulla to the right caudate nucleus in two patients with intractable Parkinson’s disease. N Engl J Med 1987;316:831–44.PubMedCrossRefGoogle Scholar
  35. 35.
    Borlongan C, Cahill D, Freeman T, Sanberg P. Recent advances in neural transplantation: relevance to neurodegenerative disorders. J Fl Med Assoc 1994;91:689–94.Google Scholar
  36. 36.
    Breeze R, Trent W, Freed C. Implanatation of fetal tissue for the management of Parkinson’s disease: a technical note. Neurosurgery 1995;36:1044–8.PubMedCrossRefGoogle Scholar
  37. 37.
    Lindvall O, Sawle G, Widner H, et al. Evidence of long-term survival and function of dopaminergic grafts in progressive Parkinson’s disease. Ann Neurol 1994;35:172–80.PubMedCrossRefGoogle Scholar
  38. 38.
    Spencer D, Robbins R, Naftolin F, et al. Unilateral transplantation of human fetal mesencephalic tissue into the caudate nucleus of patients with Parkinson’s disease. N Engl J Med 1992;327:1541–8.PubMedCrossRefGoogle Scholar
  39. 39.
    Freed C, Breeze R, Rosenberg N, et al. Survival of implanted dopamine cells and neurologic improvement 12 to 46 months after transplantation for Parkinson’s disease. N Engl J Med 1992;327:1549–55.PubMedCrossRefGoogle Scholar
  40. 40.
    Koller WC, Langston JW, Hubble JP, et al. Does a long preclinical period occur in Parkinson’s disease? Neurology 1991;41 Suppl 2:8–13.PubMedCrossRefGoogle Scholar
  41. 41.
    Ahlskog JE, Wilkinson JM. New concepts in the treatment of Parkinson’s disease. Am Fam Physician 1990;41:574–84.PubMedGoogle Scholar
  42. 42.
    Ganzini L, Casey DE, Hoffman WF, McCall AL. The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders. Arch Intern Med 1993;153:1469–75.PubMedCrossRefGoogle Scholar
  43. 43.
    Klawans HL, Stein RN, Tanner CM, Goetz CG. A pure parkinsonian syndrome following acute carbon monoxide poisoning. Arch Neurol 1982;38:302–4.CrossRefGoogle Scholar
  44. 44.
    Langston IN, Ballard PA, Tetrud JW, Irwin I. Chronic parkinsonism in humans due to a product of meperidine analog synthesis. Science 1983;219:979–80.PubMedCrossRefGoogle Scholar
  45. 45.
    Ballard PA, Tetrud JW, Langston JW. Permanent human parkinsonism due to 1-methyl-n-phenyl-1,2,3,6-tetrahydropyridine (MPTP): seven cases. Neurology 1985;35:949–56.PubMedCrossRefGoogle Scholar
  46. 46.
    Roos R, Gadjusek DC, Gibbs CJ. The clinical characteristics of transmissible Creutzfeldt-Jakob disease. Brain 1973;96(1): 1–20.PubMedCrossRefGoogle Scholar
  47. 47.
    Daniel SE, de Bruin VM, Lees AJ. The clinical and pathological spectrum of Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy): a reappraisal. Brain 1995;118:759–70.PubMedCrossRefGoogle Scholar
  48. 48.
    Jankovic J. Parkinsonism-plus syndromes. Mov Disord 1989; 4 Suppl 1:106–9.Google Scholar
  49. 49.
    Takel Y, Mirra S. Striatonigral degeneration: a form of multiple system atrophy with clinical parkinsonism. Prog Neurol Pathol 1973;2:217–51.Google Scholar
  50. 50.
    Duvoisin RC. An apology and an introduction to the olivopontocerebellar atrophies. In: Duvoisin RC, Plaitakis A, editors. The olivopontocerebellar atrophies. New York: Raven, 1984:5–12.Google Scholar
  51. 51.
    Findley LJ, Koller WC. Essential tremor: a review. Neurology 1987;37:1194–7.PubMedCrossRefGoogle Scholar
  52. 52.
    Growdon JH, Shahani BT, Young RR. The effect of alcohol on essential tremor. Neurology 1975;25:259–62.PubMedCrossRefGoogle Scholar
  53. 53.
    Hubble JP, Busenbark KL, Koller WC. Essential tremor. Clin Neuropharmacol 1989;12:453–82.PubMedCrossRefGoogle Scholar
  54. 54.
    Koller WC, Vetere-Overfield B. Acute and chronic effects of propranolol and primidone in essential tremor. Neurology 1989;39:1587–8.PubMedCrossRefGoogle Scholar
  55. 55.
    Koller WC, Royse VL. Efficacy of primidone in essential tremor. Neurology 1986;36:121–24.PubMedCrossRefGoogle Scholar
  56. 56.
    Muenter MD, Daube JR, Caviness JN, Miller PM. Treatment of essential tremor with methazolamide. Mayo Clin Proc 1991;66:991–7.PubMedCrossRefGoogle Scholar
  57. 57.
    Pahwa R, Busenbark K, Swanson-Hyland EF, et al. Botulinum toxin treatment of essential head tremor. Neurology 1995;45:822–4.PubMedCrossRefGoogle Scholar
  58. 58.
    Jankovic J, Fahn S. Dystonic syndromes. In: Jankovic J, Tolosa E, editors. Parkinson’s disease and movement disorders. Baltimore: Urban & Schwarzenberg, 1988:283–314.Google Scholar
  59. 59.
    Clinical use of botulinum toxin. NIH Consensus Development Conference Consensus Statement. 1990;8(8):1–20.Google Scholar
  60. 60.
    Casey DE. Tardive dyskinesia. West J Med 1990;153:535–41.PubMedGoogle Scholar
  61. 61.
    Jeste DV, Caligieri MP. Tardive dyskinesia. Schizophr Bull 1993;19:303–15.PubMedCrossRefGoogle Scholar
  62. 62.
    Andrew HG. Clinical relationship of extrapymidal symptoms and tardive dyskinesia. Can J Psychiatry 1994;39 Suppl 12:576–80.Google Scholar
  63. 63.
    Cadet JL, Kahler LA. Free radical mechanisms in schizophrenia and tardive dyskinesia. Neurosci Biobehav Rev 1994;18:457–67.PubMedCrossRefGoogle Scholar
  64. 64.
    Baldessarini J. A summary of current knowledge of tardive dyskinesia. L’Encephale 1988;14:263–8.PubMedGoogle Scholar
  65. 65.
    Jankovic J. Diagnosis and classification of tics and Tourette’s syndrome. Adv Neurol 1992;58:7–14.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1998

Authors and Affiliations

  • Eduardo C. Gonzalez
  • H. James Brownlee

There are no affiliations available

Personalised recommendations